Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Toremifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 9/20 | 0.80 |
| ▸ | ESR2 known ✓ | Q92731 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | THPO | P40225 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toremifene SCHEMBL15576158 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL2367538 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL177941 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL30053819 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL21464516 | 0.96 | ESR1 (0.87) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL15865397 | 0.89 | ESR1 (0.67) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL4019370 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL5328781 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL10336277 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL17164701 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34947 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| EP-4694915-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| EP-4694914-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | claimed |
| US-12544387-B2 | Methods and compositions for testosterone production | SEPAH SAVIZ CAMERON (US) | 2026-02-10 | — | — | US | claimed |
| US-12533364-B2 | Methods and compositions for testosterone production | Saviz SEPAH (US) | 2026-01-27 | — | — | US | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| WO-2001082949-A2 | METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | SCICLONE PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| US-20010018919-A1 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response | DIMENSIONAL DOSING SYSTEMS, INCORPORATED | 2001-09-06 | — | — | US | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000020022-A1 | METHODS FOR THE TREATMENT OF CANCER USING CYTOKINES IN COMBINATION WITH LOW LEVEL DOSES OF CHEMOTHERAPY AND/OR RADIOTHERAPY | LT TECHNOLOGY COMPANY, LLC. (US) | 2000-04-13 | — | — | WO | claimed |
| CN-1219919-A | Soluble oxides for biological applications | ORION YHTYM OY (FI) | 1999-06-16 | — | — | CN | claimed |
| EP-0906243-A1 | DISSOLVABLE OXIDES FOR BIOLOGICAL APPLICATIONS | ORION CORPORATION (ORION-YHTYMA OY) (FI) | 1999-04-07 | — | — | EP | claimed |
| WO-1997045367-A1 | DISSOLVABLE OXIDES FOR BIOLOGICAL APPLICATIONS | Orion-Yhtymä Oy (FI) | 1997-12-04 | — | — | WO | claimed |